NasdaqCM:CPRXBiotechs
Catalyst Pharmaceuticals (CPRX) Q1 EPS Beat Reinforces High Margin Bull Narratives
Catalyst Pharmaceuticals (CPRX) opened Q1 2026 with total revenue of US$149.4 million and basic EPS of US$0.52, setting a clear marker for how the year is starting. The company has seen quarterly revenue range from US$141.4 million in Q1 2025 to US$152.6 million in Q4 2025, while basic EPS moved between US$0.43 and US$0.47 over that period, giving you a solid view of how the top and bottom line have been tracking into the latest print. With a trailing net profit margin of 37.1% and earnings...